This open-label Phase 1 study evaluates whether eloralintide changes the way the body processes a combined oral contraceptive in women with obesity or overweight. Participation is planned to last about 8 months with three stays in the research unit. It lists 2 United States sites. The registered start month (2026-09) has passed and the registry still shows the study as not yet recruiting.
Read with care: it is a drug-interaction study, not a weight-loss study. A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.
Study context
What the study tests
This Phase 1 open-label study checks whether eloralintide changes how the body handles a combined oral contraceptive (levonorgestrel and ethinyl estradiol) in women with obesity or overweight. The primary endpoints are the drug levels of the two contraceptive components: total exposure (AUC), peak concentration and time to peak. The record lists 34 participants, and each is in the study for about eight months, including three stays of six to eight nights.
Who can take part
Women aged 18 to 60 need a BMI from 27 to 35 and a stable body weight, and must either use non-hormonal contraception or be unable to become pregnant. A history of blood clots, liver disease or breast, uterine or ovarian cancer excludes participation, as does any oral contraceptive use in the previous three months. Sites are in Florida and Texas.
What the registry does not say
No results are posted. This is a drug interaction study, so it measures levels of the contraceptive and not of eloralintide, and it registers no efficacy measure. Primary completion is planned for June 2027.
Source: ClinicalTrials.gov record NCT07808060, read on 2026-10-15. Registered plans can change.